This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immudyne Appoints Karen Kingston, Former Brand Strategist For Johnson & Johnson, Pfizer, And Allergan, To Lead Global Marketing And Sales

NEW YORK, March 25, 2013 (GLOBE NEWSWIRE) -- Immudyne, Inc. (OTCQB:IMMD) announced today that Karen Kingston has been appointed as the company's Chief Marketing Officer to lead its global sales and marketing efforts.

Ms. Kingston has 15 years of experience successfully building brands and sales strategies within the men's health, eye care, skin care, immunology, and wellness industries. Most recently Ms. Kingston served as President & CEO of Varitage. Founded in 2007, Ms. Kingston leveraged her marketing expertise and technical knowledge to quickly secure Fortune 500 clients, including Johnson & Johnson, Medtronic, and Pfizer. Ms. Kingston also secured numerous medical device clients throughout the west coast, including OASIS Medical, Revision Optics, and Lumenis. Ms. Kingston has a stellar track record of transforming stagnant product portfolios into highly visible brands with accelerated revenue growth.

Prior to Varitage, Ms. Kingston spent more than 10 years working in sales and marketing for Pfizer, Allergan, and medical advertising agencies. She played a key role in marketing Viagra and was integral to shifting the brand focus to younger men and overall wellness.

"We are seeing increasing market demand for our Yeast Beta Glucan product line," said Mark McLaughlin, President & CEO of Immudyne. "Karen's know-how and proven ability to properly position and grow medical and wellness brands will be invaluable to us as we introduce new product lines from Immudyne's global portfolio."

As Chief Marketing Officer,  Ms. Kingston will spearhead the launch of several new product lines based upon Immudyne's proprietary and patented Yeast Beta Glucan.  She will also be responsible for the continued growth and management of Immudyne's sales and marketing team as well as the company's R&D of new product development initiatives.

"I believe there is tremendous opportunity to educate consumers on how critical the immune system is to overall health. Many adults are unaware that by taking simple actions to support their immune system, they can feel better, look better, and live healthier lives," said Ms. Kingston. "I am thrilled to have the opportunity to lead the marketing and sales efforts at Immudyne. Our products offer unique and meaningful benefits for both men and women and will help improve many, many lives."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs